Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 4/20 | 0.59 |
| ▸ | BRD4 | O60885 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | PNMT | P11086 | 3/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22955423 | 1.00 | CREBBP (0.59) | CREBBPBRD4GAAMAPTMTNR1A | |
| Naphthalene SCHEMBL7012339 | 0.94 | CREBBP (0.54) | CREBBPBRD4GAAMAPTMTNR1A | |
| SCHEMBL550098 | 0.85 | CREBBP (0.44) | CREBBPBRD4GAAMAPTMTNR1A | |
| SCHEMBL28923868 | 0.82 | ALDH1A1 (0.43) | CREBBPBRD4GAAMAPTMTNR1A | |
| SCHEMBL11426860 | 0.82 | GAA (0.47) | CREBBPBRD4GAAMAPTMTNR1A | |
| SCHEMBL22262591 | 0.81 | MTNR1A (0.60) | CREBBPBRD4GAAMAPTMTNR1A | |
| SCHEMBL29659944 | 0.81 | MTNR1A (0.60) | CREBBPBRD4GAAMAPTMTNR1A | |
| SCHEMBL20870486 | 0.81 | MTNR1A (0.60) | CREBBPBRD4GAAMAPTMTNR1A | |
| SCHEMBL4139663 | 0.81 | MTNR1A (0.60) | CREBBPBRD4GAAMAPTMTNR1A | |
| SCHEMBL29659962 | 0.81 | MTNR1A (0.60) | CREBBPBRD4GAAMAPTMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| CN-110437123-B | Method for synthesizing optically pure 2-substituted indoline compound through dynamic kinetic resolution | 华中师范大学 | 2023-01-03 | — | — | CN | disclosed |
| US-11174242-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2021-11-16 | — | — | US | disclosed |
| WO-2020147848-A1 | TRICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-07-23 | — | — | WO | disclosed |
| US-10399980-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3356345-A1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2018-07-24 | — | — | US | disclosed |
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-31 | — | — | US | disclosed |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-31 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| EP-1757584-A1 | Heterocyclic substituted amides, their production and their use | Abbott GmbH & Co. KG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-4110070-A | QUATERNIZING INDOLENINE METHINE COMPOUND ON FIBERS TO FORM CATIONIC DYE | HODOGAYA CHEMICAL CO., LTD. (JP) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | CREBBP 2082/4885BRD4 1294/4885GAA 852/4885 |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | AREG, TGFB1, TGFB2 | CREBBP 2276/4885BRD4 2440/4885GAA 1053/4885 |
| US-10399980-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | CREBBP 1887/4885BRD4 528/4885GAA 1605/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | CREBBP 2046/4885BRD4 4039/4885GAA 4235/4885 |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NR0B1, NR2E1, NR0B2 | CREBBP 295/4885BRD4 850/4885GAA 1099/4885 |
| US-11174242-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | CREBBP 4327/4885BRD4 3068/4885GAA 3/4885 |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | CREBBP 963/4885BRD4 2304/4885GAA 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.